Corvus Pharmaceuticals (NASDAQ:CRVS) is up another 9.1% today, trading on volume that’s more than 16 times its average.
That’s part of recent moves coinciding with increased stakes by members of management as well as the company’s top shareholder, all following information from a Phase 1/1b trial in patients with advanced refractory cancer.
After Tuesday’s close, top shareholder OrbiMed disclosed holdings boosted to a 22.6% stake, and shares rose 25.5% on Wednesday.
That followed purchases last month by CEO Richard Miller and Chief Financial Officer Leiv Lea.
The shares are about 40.5% below their level a year ago, but have risen 90.9% in a week and gained 55.2% over the past month.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.